High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma
- 1 March 2006
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 6 (3) , 343-360
- https://doi.org/10.1586/14737140.6.3.343
Abstract
Multiple myeloma, for all practical purposes, remains an incurable malignancy; however, 5-year survival has improved substantially during the past 30 years. A major contribution to improved outcome is the use of high-dose chemotherapy and stem cell transplantation. This multifaceted approach to therapy requires an understanding of appropriate induction therapy, techniques for stem cell mobilization, appropriate conditioning and supportive care. Also of importance are prognosis, features that predict outcome, the suitability of transplant candidates, and post-transplantation maintenance therapy.Keywords
This publication has 100 references indexed in Scilit:
- Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myelomaBlood, 2005
- PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myelomaBritish Journal of Haematology, 2005
- Myeloma cell contamination of peripheral blood stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantationZeitschrift für Krebsforschung und Klinische Onkologie, 2004
- Activity of single-agent melphalan 220–300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphomaBone Marrow Transplantation, 2004
- Single versus Double Autologous Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2003
- Thalidomide as initial therapy for early-stage myelomaLeukemia, 2003
- Infectious complications after autologous hematopoietic stem cell transplantation: comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myelomaAnnals of Hematology, 2002
- Myeloablative Treatments for Multiple Myeloma: Update of a Comparative Study of Different Regimens Used in Patients from the Spanish Registry for Transplantation in Multiple MyelomaLeukemia & Lymphoma, 2002
- Prospective randomized clinical trial comparing high-dose ifosfamide + GM-CSF vs high-dose cyclophosphamide + GM-CSF for blood progenitor cell mobilizationBone Marrow Transplantation, 2000
- Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first‐line treatment in untreated multiple myelomaBritish Journal of Haematology, 1999